VERA - Vera Therapeutics, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$87.14
DETAILS
HIGH:
$125.00
LOW:
$43.00
MEDIAN:
$90.00
CONSENSUS:
$87.14
UPSIDE:
107.48%
About Vera Therapeutics, Inc. (https://veratx.com)
Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United States. Their leading therapeutic candidate is atacicept, a fusion protein that patients self-administer as a subcutaneous injection. This drug is currently undergoing Phase IIb clinical trials to treat immunoglobulin A nephropathy. The company is also advancing MAU868, a monoclonal antibody in Phase 2 clinical development, designed to combat BK viremia infections. Founded in 2016 and based in Brisbane, California, the organization operated as Trucode Gene Repair, Inc. until it rebranded to Vera Therapeutics, Inc. in April 2020.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Marshall Fordyce | Founder, President, Chief Executive Officer & Director | 1975 | $1,214,400 USD |
| David L. Johnson | Chief Opearating Officer | 1970 | $798,600 USD |
| Robert Brenner | Chief Medical Officer | 1968 | $797,040 USD |
| Sean Grant | Chief Financial Officer | 1985 | $793,920 USD |
| William D. Turner | Chief Regulatory Officer | 1967 | $737,880 USD |
| Debra Charlesworth | Vice President of Corporate Communications | – | – |
| Emma Haywood | Vice President of Marketing | – | – |
| Jane Wright-Mitchell | Chief Legal Officer & Secretary | 1969 | – |
| Joseph R. Young | Senior Vice President of Finance & Chief Accounting Officer | 1972 | – |
| S. Sandra Park | Senior Vice President of Legal, Healthcare,Commercial Law, Compliance & Operations | – | – |